CDK4 and breast cancer: The requirement of wild-type TP53 for the efficacy of CDK4/6 inhibitors may also relate to their efficacy in breast cancers, where ER-positive breast cancers bear mutations of TP53 only rarely, while triple-negative cancers, which are resistant, have such mutations in 90% of cases [50,51].